Compounds > spironolactone
Page last updated: 2024-08-17

spironolactone and letrozole

spironolactone has been researched along with letrozole in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's2 (18.18)24.3611
2020's8 (72.73)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Adeyanju, OA; Fabunmi, OA; Falodun, TO; Olatunji, LA; Soladoye, AO1
Adeyanju, OA; Agbana, RD; Falodun, TO; Michael, OS; Oyewole, AL; Soetan, OA1
Adeyanju, OA; Ojulari, LS; Olaiya, OE; Olaniyi, KS; Omoaghe, AO; Oniyide, AA1
Dehghan, Z; Mirmotalebisohi, SA; Mohammadi-Yeganeh, S; Salehi, M; Sameni, M; Zali, H1
Brady, PH; Gin, GT; Rosenblum, E; Wilkinson, LD1
Akintayo, CO; Areloegbe, SE; Aturamu, A; Olaniyi, KS; Oniyide, AA; Peter, MU1
Chen, R; Lin, X; Yang, X; Yuan, X; Zhang, Y1
Areloegbe, SE; Olaniyi, KS; Oyeleke, MB; Peter, MU1
Agbana, RD; Ajadi, IO; Areloegbe, SE; Areola, ED; Atuma, CL; Fafure, AA; Olaniyi, KS; Olatunji, LA; Sabinari, IW; Shah, MZUH1

Reviews

1 review(s) available for spironolactone and letrozole

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

10 other study(ies) available for spironolactone and letrozole

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone.
    Chemico-biological interactions, 2019, Sep-01, Volume: 310

    Topics: Androgen Antagonists; Animals; Female; Insulin Resistance; Letrozole; Luteinizing Hormone; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Rats; Rats, Wistar; Spironolactone; Testosterone

2019
Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid-a familiar foe.
    Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:6

    Topics: Animals; Female; Letrozole; Liver; Ovary; Polycystic Ovary Syndrome; Rats; Rats, Wistar; Spironolactone; Triglycerides; Uric Acid

2020
Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS.
    Toxicology and applied pharmacology, 2021, 01-15, Volume: 411

    Topics: Adiponectin; Animals; Biomarkers; Disease Models, Animal; Female; Inflammation Mediators; Letrozole; Lipids; Mineralocorticoid Receptor Antagonists; Ovarian Follicle; Ovary; Polycystic Ovary Syndrome; Prolactin; Rats, Wistar; Spironolactone; Testosterone

2021
Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis.
    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2021, Volume: 29, Issue:2

    Topics: Computational Biology; Databases, Protein; Drug Repositioning; Female; Gene Expression Regulation; Humans; Letrozole; Metformin; Phosphatidylinositol 3-Kinases; Pioglitazone; Polycystic Ovary Syndrome; Protein Interaction Maps; Proteomics; Proto-Oncogene Proteins c-akt; Signal Transduction; Spironolactone

2021
Female Pelvic Conditions: Polycystic Ovary Syndrome.
    FP essentials, 2022, Volume: 515

    Topics: Acne Vulgaris; Anovulation; Female; Finasteride; Gonadotropin-Releasing Hormone; Hirsutism; Humans; Hyperandrogenism; Infertility; Letrozole; Male; Obesity; Polycystic Ovary Syndrome; Spironolactone; Weight Loss

2022
Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model.
    Canadian journal of physiology and pharmacology, 2022, Sep-01, Volume: 100, Issue:9

    Topics: Animals; bcl-2-Associated X Protein; Disease Models, Animal; Female; Humans; Inflammasomes; Letrozole; Polycystic Ovary Syndrome; Rats; Rats, Wistar; Spironolactone

2022
Long-Term Treatment With Letrozole in a Boy With Familial Male-Limited Precocious Puberty.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adult; Child; Child, Preschool; Humans; Letrozole; Male; Puberty, Precocious; Spironolactone; Triptorelin Pamoate

2022
Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model.
    BMC endocrine disorders, 2022, Sep-07, Volume: 22, Issue:1

    Topics: Adipose Tissue; Animals; Apoptosis; Female; Humans; Inflammation; Letrozole; Polycystic Ovary Syndrome; Rats; Rats, Wistar; Spironolactone

2022
Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome.
    Toxicology and applied pharmacology, 2023, Aug-15, Volume: 473

    Topics: Animals; Dyslipidemias; Female; Humans; Inflammation; Letrozole; NLR Family, Pyrin Domain-Containing 3 Protein; Polycystic Ovary Syndrome; Proprotein Convertase 9; Rats; Rats, Wistar; Receptors, LDL; Spironolactone

2023